The American Journal of Psychiatry
Journal Home Search Current Issue Past Issues Subscribe All APPI Journals Help Contact Us
 
Quicksearch
Advanced Search
Or Search All APPI Journals
This Article
* Full Text
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
Services
* Email this article to a Colleague
* Similar articles in this journal
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via HighWire
* Citing Articles via Google Scholar
Google Scholar
* Articles by Henry, M. E.
* Articles by Renshaw, P. F.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by Henry, M. E.
* Articles by Renshaw, P. F.
Related Collections
* Depression
* Antidepressants
* MRS
Am J Psychiatry 157:1506-1508, September 2000
© 2000 American Psychiatric Association


Brief Report

Brain Kinetics of Paroxetine and Fluoxetine on the Third Day of Placebo Substitution: A Fluorine MRS Study

Michael E. Henry, M.D., Constance M. Moore, Ph.D., Marc J. Kaufman, Ph.D., David Michelson, M.D., Mark E. Schmidt, M.D., Eve Stoddard, Alexander J. Vuckevic, M.D., Paul J. Berreira, M.D., Bruce M. Cohen, M.D., Ph.D., and Perry F. Renshaw, M.D., Ph.D.

OBJECTIVE: This study tested whether a relationship exists between concentration and response following discontinuation of selective serotonin reuptake inhibitors. METHOD: Eight patients with remitted major depression who were taking 20 mg/day of either fluoxetine or paroxetine underwent placebo substitution for 3 days. Serum drug and brain fluorine levels were obtained before and after placebo substitution. RESULTS: With placebo substitution, a mean of 88% (SD=13%) of brain fluorine signal from fluoxetine (plus fluorinated metabolites) remained, compared with a mean of 38% (SD=17%) of the brain fluorine signal from paroxetine (plus fluorinated metabolites). Among patients taking paroxetine, adverse events during placebo substitution correlated highly with steady-state brain drug levels. CONCLUSIONS: The correlation of clinical effects with brain drug levels in the paroxetine group suggests that relationships between drug response and brain drug concentrations merit further investigation.




This article has been cited by other articles:


Home page
J. Neurosci.Home page
B. Eisensamer, M. Uhr, S. Meyr, G. Gimpl, T. Deiml, G. Rammes, J. J. Lambert, W. Zieglgansberger, F. Holsboer, and R. Rupprecht
Antidepressants and Antipsychotic Drugs Colocalize with 5-HT3 Receptors in Raft-Like Domains
J. Neurosci., November 2, 2005; 25(44): 10198 - 10206.
[Abstract] [Full Text] [PDF]


Home page
Am. J. PsychiatryHome page
W. L. Strauss, A. S. Unis, C. Cowan, G. Dawson, and S. R. Dager
Fluorine Magnetic Resonance Spectroscopy Measurement of Brain Fluvoxamine and Fluoxetine in Pediatric Patients Treated for Pervasive Developmental Disorders
Am J Psychiatry, May 1, 2002; 159(5): 755 - 760.
[Abstract] [Full Text] [PDF]




Get information about faster international access.

Privacy Policy

Copyright © 2000 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us

American Psychiatric Publishing, Inc. American Psychiatric Association
1000 Wilson Boulevard, Suite 1825, Arlington, VA 22209-3901 * 800-368-5777 * appi at psych.org